Profil:
Neuca SAPublikacja: 2025-08-28 07:40
Neuca pharma posts Q2 EBITDA of PLN 74.6 mln
Listed pharmaceutical company Neuca posted second quarter 2025 EBITDA of PLN 74.6 million (EUR 17.5 mln) and attributable net profit of PLN 19.8 million (EUR 4.6 mln), the company said in its finanacial report.
PLN mln
2Q2025 | results | consensus | difference | y/y | q/q | YTD 2025 | y/y |
Revenues | 3268.0 | 3208.7 | 1.8% | 7.4% | -2.9% | 6633.9 | 6.9% |
EBITDA | 74.6 | 83.9 | -11.1% | -19.3% | -33% | 185.1 | -10.8% |
EBIT | 43.2 | 52.0 | -17.0% | -30.7% | -46% | 122.5 | -17.4% |
Attrib. net profit | 19.8 | 27.1 | -26.9% | -35.3% | -59.1% | 68.2 | -21.7% |
EBITDA margin | 2.3% | 2.6% | -0.33 | -0.75 | -1.00 | 2.79% | -0.55 |
EBIT margin | 1.3% | 1.6% | -0.30 | -0.73 | -1.03 | 1.85% | -0.54 |
net margin | 0.6% | 0.8% | -0.24 | -0.40 | -0.83 | 1.03% | -0.37 |
doa/ nl/